2022ReviewDrug Delivery
Lei W, Yang C, Wu Y, Ru G, He X, Tong X, Wang S.
Conventional chemotherapy suffers from poor targeting and severe side effects, while synthetic nanocarriers are often cleared by the immune system and lack precise tumor targeting. Cell membrane-coated nanocarriers (CMCNs) offer a biomimetic strategy to improve biocompatibility, immune evasion, circulation time, and homotypic tumor targeting. RBC membrane-coated PLGA nanocarriers improved blood retention to 72 hours vs 15.8 hours for typical PEGylated stealth nanocarriers. - Neutrophil membrane-coated nanocarriers showed 2–3-fold higher accumulation in.
Read the article →Chemical Society Reviews* (as indicated by review format; exact volume/pages and DOI not included in the supplied file)2021ReviewNon-viral Gene Delivery
Yingshu Guo, Xiuping Cao, Xiaofei Zheng, Sk Jahir Abbas, Juan Li, Weihong Tan
Cancer treatment still relies heavily on chemotherapy, which causes severe damage to normal cells and systemic side effects. Safer, more selective drug delivery strategies are needed. Nanocarriers based on nucleic acids (NCNAs) are attractive because nucleic acids offer biocompatibility, low toxicity, programmable structures, controllable size, and modifiability—advantages that address limitations of cationic polymers, dendrimers, and inorganic nanoparticles. --- - DNA tetrahedron loaded with 5-fluorouracil: after 12 h co-incubation, the percentage of drug in cells was nearly 40%, demonstrating stable and efficient drug delivery. - DNA/RNA hybrid spherical nucleic acid with siRNA: rapidly absorbed by more than 60 kinds of cells; protected siRNA from enzymatic digestion and released it upon intracellular Dicer cleavage. - Se/Ru metal–organic nanoparticles + siRNA: enhanced cell uptake and promoted siRNA escape from endosomes/lysosomes, p
Read the article →Signal Transduction and Targeted Therapy2021ReviewNon-viral Gene Delivery
Chen L, Hong W, Ren W, Xu T, Qian Z, He Z.
Synthetic nanoparticles face physiological barriers, RES clearance, and unintended biological interactions despite PEGylation and ligand grafting. Biological vectors—cell membranes, extracellular vesicles (EVs), and viruses—offer biocompatibility, biodegradability, immune evasion, and natural targeting. This review summarizes BNPs integrating biological vectors with functional agents for targeted delivery in imaging and therapy. RBCM-coated PLGA nanoparticles improved half-life by ~50% vs PEGylated nanoparticles and were detected in circulation after 72 h. - NM-NP-CFZ (neutrophil membrane-coated carfilzomib PLGA NPs) reduced lung metastasis by.
Read the article →Bioactive Materials2021ReviewNon-viral Gene Delivery
Muyue Yang, Jipeng Li, Ping Gu, Xianqun Fan
Tumor microenvironment (TME) modulation is a promising strategy in cancer immunotherapy, but conventional immunotherapeutic agents suffer from limited drug retention in the TME, severe adverse events, and low response rates. Nanoparticles can prolong retention, enable targeted delivery to TME components, and convert the immunosuppressive TME into an immunosupportive state, potentially improving therapeutic efficacy while reducing toxicity. DC targeting: CD40-targeted PLGA nanoparticles achieved highest binding/uptake and maximum IL-12 production in vitro; however, T cell proliferation was driven mainly by TLR ligands rather than targeting ligand. -.
Read the article →Molecules2021ReviewNon-viral Gene Delivery
Wan, Z.; Zheng, R.; Moharil, P.; Liu, Y.; Chen, J.; Sun, R.; Song, X.; Ao, Q
Cancer immunotherapy can produce durable clinical responses, but systemic delivery of immunostimulatory agents is limited by short half-lives, off-target toxicities (e.g., cytokine release syndrome), low response rates (10–30%), and poor efficacy in solid tumors. Polymeric micelles offer a biocompatible, modifiable, core–shell delivery platform that can improve bioavailability, enable tumor accumulation via the EPR effect, and reduce systemic. IL-2 micelles: Enhanced DC vaccine efficacy and increased antigen-specific CTL accumulation at tumor sites. - PMet-P(cdmPEG2K) micelles: Co-delivery of DOX and pIL-12 was more effective at inhibiting tumor growth than.
Read the article →Frontiers in Molecular Biosciences2020ReviewDrug Delivery
Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A.
Conventional chemotherapy and targeted therapy are limited by systemic toxicity, poor tumor targeting, and multidrug resistance (MDR). Nanoparticle-based drug delivery offers improved pharmacokinetics, biocompatibility, enhanced permeability and retention (EPR), precise targeting, and potential to overcome resistance mechanisms such as efflux transporters, defective apoptosis, and hypoxia. NPs with diameters of 10–100 nm are generally suitable for cancer therapy; <10 nm are cleared by kidneys, >100 nm are cleared by phagocytes. - PEGylation reduces opsonization and immune clearance, prolonging.
Read the article →Oncology Reports2019ReviewNon-viral Gene Delivery
Rimjhim Mohanty, Chitran Roy Chowdhury, Solomon Arega, Prakriti Sen, Pooja Ganguly, Niladri Ganguly
Cancer is a leading cause of mortality worldwide, and conventional treatments and cytotoxic immunotherapies have limitations. Because tumors are complex and involve multiple genetic and cellular factors in tumorigenesis and metastasis, there is a need for an immunotherapy that targets tumors at both cellular and genetic levels. CAR T cell therapy has emerged as a novel T cell engineering practice, and this review synthesizes its advantages, advances, and differences from chemotherapy and radiotherapy. --- - CAR T cell therapy achieved remission rates of up to 80% in hematologic cancers, particularly ALL and non-Hodgkin lymphomas. - Second-generation anti-CD19 CARs achieved complete remission rates of up to 90% in patients with recurrent B-cell ALL. - ELIANA trial: tisagenlecleucel produced a 3-month complete remission rate of 83% and a 6-month survival rate of 89%. - ZUMA-1 trial: axicabtagene ciloleucel produced an 82% overall response
Read the article →Drug Delivery2018ResearchDrug Delivery
Juan Chen, Xiaobing Yang, Liuqing Huang, Huixian Lai, Chuanhai Gan, Xuetao Luo
Lung cancer has the highest mortality among cancers, and single-agent chemotherapy is often unsuccessful due to drug resistance, insufficient intracellular uptake, nonspecific targeting, and severe systemic toxicity. Combination chemotherapy can suppress drug resistance and achieve synergistic anticancer efficacy, but there is a need for targeted nanocarrier systems that can co-deliver multiple chemotherapeutic agents while providing active. ### Nanoparticle Characterization | Parameter | Result | |---------------|------------| | Hydrodynamic diameter (DLS) | 176 nm | | TEM core diameter | ~80 nm | | Polydispersity index (PDI) | 0.109 ± 0.034 | | Zeta.
Read the article →Colloids and Surfaces B: Biointerfaces2018ResearchDrug Delivery
Amirhossein Bahreyni, Mona Alibolandi, Mohammad Ramezani, Atefeh Sarafan Sadeghi, Khalil Abnous, Seyed Mohammad Taghdisi
Conventional chemotherapy for breast and colon cancers suffers from low specificity, rapid drug clearance, and severe toxic side effects on healthy tissues, while chemoresistance and metastasis remain major causes of cancer-related mortality. There is an unmet need for targeted delivery systems that can co-deliver chemotherapeutic agents with oligonucleotide-based therapeutics (e.g., miRNA inhibitors) to enhance efficacy and reduce off-target. Epi Release Profile: - ~80% Epi released at pH 5.5 (tumor tissue/lysosomal pH) after 72 h - ~28% Epi released at pH 7.4 (physiological blood pH) after 72 h - Demonstrates pH-responsive release mediated by PβAE.
Read the article →Frontiers in Immunology.2017ReviewDrug Delivery
Mizrahy S, Hazan-Halevy I, Landesman-Milo D, Ng Bd, Peer D
Current cancer immunotherapy shows promise but fails across many tumor types, likely because single-pathway treatments cannot overcome the complex immunosuppressive tumor microenvironment (TME). Lipid-based nanoparticles (LNPs) may allow simultaneous, temporally coordinated delivery of multiple immune modulators to improve antitumor responses while reducing toxicity. Review-level findings include: - Co-delivery of antigen and adjuvant to the same antigen-presenting cell boosts immunogenicity; ICMVs elicited stronger antibody and CTL responses than simple liposomes. - RNA-LPX.
Read the article →Drug Delivery2016ResearchDrug Delivery
Jie Qu, Liangqiao Zhang, Zhihua Chen, Guohua Mao, Ziyun Gao, Xianliang Lai, Xingen Zhu, Jianming Zhu
Glioblastoma multiforme (GBM) has a poor prognosis due to limited drug delivery across the blood–brain barrier (BBB), therapeutic resistance, and recurrence. Nanocarriers may improve temozolomide (TMZ) delivery, but it is unclear which nanocarrier type—polymeric nanoparticles (PNPs), solid lipid nanoparticles (SLNs), or nanostructured lipid carriers (NLCs)—is optimal for glioblastoma chemotherapy. Particle properties: All formulations were ~95–121 nm, spherical. T-PNPs were anionic; T-SLNs and T-NLCs were cationic. EE >80% for all; DL highest for T-PNPs (10.8%) and lowest for T-NLCs (5.2%). - Serum stability: All.
Read the article →2016ReviewDrug Delivery
Rizwanullah M, Ahmad J, Amin S
Conventional cancer chemotherapy suffers from poor drug specificity, narrow therapeutic windows, high dose-limiting toxicity, and multidrug resistance (MDR). Nanostructured lipid carriers (NLCs) are biocompatible, biodegradable lipid-based nanoparticles that can improve solubility, stability, targeting, and controlled release of chemotherapeutics, potentially overcoming limitations of solid lipid nanoparticles (SLNs) and conventional delivery. PTX–DOX co-loaded NLCs had a mean size of 129.3 ± 4.2 nm and showed excellent cytotoxicity in NCI-H460 cells and in a human NSCLC xenograft model. - Curcumin NLCs (~214 nm) enhanced brain tumor inhibitory efficiency to.
Read the article →International Journal of Nanomedicine2015ResearchDrug Delivery
Chun-Ying Qu, Min Zhou, Ying-Wei Chen, Mei-Mei Chen, Feng Shen, Lei-Ming Xu
5-Fluorouracil (5-FU) plus cisplatin (CDDP) is a first-line gastric cancer chemotherapy regimen, but it causes substantial toxicity and 5-FU has poor biopharmaceutical properties. A targeted nanoparticle platform could codeliver both drugs, improve synergy, and reduce systemic toxicity. Optimal HA coating concentration was 0.2% (w/v); higher concentrations (0.3–0.4%) decreased encapsulation efficiency and increased particle size. - HA-FU/C-NLC showed sustained release: >80% 5-FU release at 48 h vs 36 h.
Read the article →International Journal of Nanomedicine2015ResearchNon-viral Gene Delivery
Zhenyu Shao, Jingyu Shao, Bingxu Tan, Shanghai Guan, Zhulong Liu, Zengjun Zhao, Fangfang He, Jian Zhao
Lung cancer chemotherapy is limited by multidrug resistance, severe adverse effects, and poor tumor targeting. A nanocarrier that actively targets lung cancer cells and co-delivers a cytotoxic drug plus therapeutic DNA could improve efficacy and reduce off-target toxicity. Tf₅ₖ-PTX-DNA-NLC: ~133 nm, zeta +19 mV; Tf₁₀ₖ-PTX-DNA-NLC: ~236 nm, zeta +8 mV. - DNA loading ~90–92%; PTX encapsulation ~83–87%. - In vitro IC₅₀: Tf₅ₖ-PTX-DNA-NLC 3.35 µM; Tf₁₀ₖ-PTX-DNA-NLC 7.12 µM; PTX-DNA-NLC 7.36.
Read the article →ACS Nano2015ResearchNon-viral Gene Delivery
Antonella Mangraviti, Stephany Yi Tzeng, Kristen Lynn Kozielski, Yuan Wang, Yike Jin, David Gullotti, Mariangela Pedone, Nitsa Buaron, Ann Liu, David R. Wilson, Sarah K. Hansen, Fausto J. Rodriguez, Guo-Dong Gao, Francesco Dimeco, Henry Brem, Alessandro Olivi, Betty Tyler, Jordan J. Green
Glioblastoma remains highly lethal with poor prognosis despite surgery, radiation, and chemotherapy. Gene therapy is a promising alternative, but viral vectors carry safety risks. Non-viral polymeric nanoparticles are safer but have historically shown poor in vivo efficacy. A biodegradable poly(beta-amino ester) (PBAE) nanoparticle system was developed to deliver a suicide gene to malignant glioma and improve survival. In vitro transfection: Ten PBAE nanoparticle formulations achieved >50% transfection with <20% toxicity in 9L cells; eight formulations in F98 cells. Three formulations were superior to Lipofectamine 2000 in 9L; fifteen.
Read the article →2014ResearchDrug Delivery
Lopes Rm, Gaspar Mm, Pereira J, Eleuterio Cv, Carvalho M, Almeida Aj, Cruz Mem
Current leishmaniasis chemotherapy lacks options that combine high activity, low toxicity, and affordable cost. Oryzalin (ORZ), a dinitroaniline with in vitro antileishmanial activity, is limited by poor water solubility and low accumulation in diseased organs. Lipid-based nanocarriers may overcome these limitations, but liposomes and solid lipid nanoparticles had not been systematically compared as ORZ carriers. Formulation: Lip-ORZ ~0.21 µm, ζ ~ −30 to −35 mV, incorporation efficiency 91–94%. LNP-ORZ ~0.17 µm, ζ ~ −22 to −24 mV, incorporation efficiency 95–97%. - In vitro toxicity: Free ORZ: HC₅₀ 425 µM, CC₅₀ 20 µM. Lip-ORZ.
Read the article →